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INTRODUCTION
Development of a ventricular septal defect (VSD) is a rare complication in transcatheter aortic valve implantations (TAVI). Therefore experience is limited even in large centers. Treatment options range from complete surgical repair to conservative treatment in this elderly patient population.
CASE REPORT
A 69-year-old female with symptomatic (NYHA III) severe aortic stenosis (valve area: 0.5 cm 2 , mean gradient 44 mmHg) was evaluated for TAVI. The patient had heavy circumferential calcifications of the ascending aorta after mediastinal radiation for nonHodgkin lymphoma 50 years earlier.
Preoperative computed tomography showed an aortic valve annulus diameter of 21 Â 26 mm with heavy calcifications extending into the left ventricular outflow tract (LVOT) (Fig. 1A) . A self-expandable 25 mm valve prosthesis (Symetis ACCURATE TA, Symetis SA, Ecublens, Switzerland) and transapical access were chosen.
Predilatation was performed and the prosthesis released for paravalvular regurgitation grade II post-dilatation was performed with a 23 mm-balloon. The postinterventional result was trace paravalvular regurgitation on transoesophageal echocardiography (TOE) and angiography (Video 1). Ten weeks later, the patient returned with new onset complete heart block and received dual chamber pacemaker implantation. Clinical examination revealed a new holoystolic heart murmur. TOE showed a shunt between the LVOT and right ventricle (RV) (Fig. 1C) . Aortography confirmed the finding (Fig. 1B) . The jet originated from within the basal prosthesis cage just below the aortic annulus. Right heart catheterization proved hemodynamic significance (Q p /Q s : 1.5/1).
The Heart Team decided for a VSD closure to prevent right heart failure. We chose a percutaneous PFO closure device with a thin waist and a diameter large enough to cover the tear and small enough to avoid interference with prosthesis leaflets on the A percutaneous approach appeared difficult since the VSD was covered by the subvalvular stent-struts.
The surgical approach was challenging due to the porcelain aorta. An aortic no-touch approach was applied using the right common carotid artery for arterial return of the cardiopulmonary bypass (CPB) circuit. Under total CPB and induced ventricular fibrillation the right atrium was opened. Visualization of the VSD required partial detachment of the septal tricuspid leaflet. A guidewire was passed through the VSD and the subvalvular stent cage into the left ventricle followed by an 8F introducer sheath. An 18 mm-Amplatzer-PFO-occluder was partially deployed and pulled back on to the LVOT-wall. Then the occluder was deployed on the RV side. An immediate closure of the defect was achieved (Fig. 2, Video 2) .
DISCUSSION
Iatrogenic VSD after TAVI is associated with heavy calcifications of the LVOT and post-dilatation. The VSD is not always immediately apparent. Reports of weeks to months until the appearance of symptoms exist [1, 2] . Small tears may increase with time when a self-expandable prosthesis causes further protrusion of calcifications.
The common treatment option for VSD after TAVI is SAVR with patch-closure of the VSD. In our case the porcelain aorta precluded a standard surgical approach including cross clamping of the aorta.
Anecdotally percutaneous approaches were successful with an antegrade arterio-venous loop technique using interventional occluders [1, 2] . The VSDs were located on the lower edges of Edwards Sapien 3-and CoreValveV R -prosthesis. In our case the VSD was located within the prosthesis cage possibly impeding passage of percutaneous delivery sheaths.
A valve-in-valve solution with coverage of the VSD was judged hazardous because of the degree and location of calcification in the LVOT.
We combined the experiences of cardiology and cardiac surgery to an individualized hybrid strategy with enhanced probability of closure success at reduced surgical risk. The Symetis valve allowed for insertion of an occluder without leaflet interference. The nadir of its native porcine leaflets is attached to a self-expanding nitinol stent 8 mm above its lower edge ( Fig. 2A ) [3] . It cannot be assumed that such devices will generally work well in different prosthesis or VSD-locations.
CONCLUSION
Closure by means of a PFO-occluder with surgical visualization is a feasible treatment option for iatrogenic VSD after TAVI. Individualized bail-out strategies are a particular treasure of an experienced interdisciplinary Heart Team.
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